US 11,786,150 B1
Wired implantable monolithic integrated sensor circuit
Muhammad Mujeeb-U-Rahman, Irvine, CA (US); Meisam Honarvar Nazari, Irvine, CA (US); and Mehmet Sencan, Tustin, CA (US)
Appl. No. 17/993,516
Filed by INTEGRATED MEDICAL SENSORS, INC., Irvine, CA (US)
PCT Filed Sep. 1, 2022, PCT No. PCT/US2022/042401
§ 371(c)(1), (2) Date Nov. 23, 2022,
PCT Pub. No. WO2023/034542, PCT Pub. Date Mar. 9, 2023.
Claims priority of provisional application 63/336,299, filed on Apr. 28, 2022.
Claims priority of provisional application 63/333,443, filed on Apr. 21, 2022.
Claims priority of provisional application 63/318,790, filed on Mar. 11, 2022.
Claims priority of provisional application 63/298,632, filed on Jan. 12, 2022.
Claims priority of provisional application 63/239,484, filed on Sep. 1, 2021.
Int. Cl. A61B 5/145 (2006.01); A61B 5/1486 (2006.01); A61B 5/00 (2006.01)
CPC A61B 5/14532 (2013.01) [A61B 5/14865 (2013.01); A61B 5/6848 (2013.01)] 4 Claims
OG exemplary drawing
 
1. A glucose sensor system comprising:
a transmitter for containing a battery, the transmitter being for placement on top of patient skin;
a transcutaneous connector comprising at least one conductive path; and
an implantable monolithic integrated circuit for placement beneath the patient skin, wherein the implantable monolithic integrated circuit comprises a potentiostat and an electrochemical sensing element;
wherein the potentiostat is electrically coupled to the transmitter via the transcutaneous connector, and the electrochemical sensing element is configured to sense glucose concentration and generate an electrical signal representative of the glucose concentration, and wherein the potentiostat is electrically connected to the electrochemical sensing element,
further comprising an analog to digital converter for placement beneath the patient skin, wherein the analog to digital converter is electrically connected to the potentiostat.